Menu
Not yet recruiting NCT07390968

Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients

Phase II Interventional Hematopoietic and Lymphatic System Neoplasm

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection, Electronic Health Record Review.
Who it may be relevant to
Registry conditions: Hematopoietic and Lymphatic System Neoplasm. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Phase 2, Multicenter, Double-Blind, Randomized, Controlled Trial of the Safety and Immunogenicity of a Self-Amplifying mRNA COVID-19 Vaccine in Adult Hematopoietic Cell Transplant Recipients

Overview

This phase IIb trial compares the effect of LUNAR-COV19 vaccine to Comirnaty vaccine in treating adult patients who have received a hematopoietic cell transplant (HCT). Guidelines recommend repeating severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination of 3 messenger ribonucleic acid (mRNA) vaccines followed by a fourth booster 3-6 months after treatment. However, vaccination is less effective in HCT patients compared to healthy people due to impaired immune responses. LUNAR-COV19, a self-amplifying mRNA vaccine, may help the body's own immune system recognize the SARS-CoV-2 spike protein and fight the virus by using a special mRNA that copies itself for a stronger response. Vaccines made from mRNA with SARS-CoV-2, such as Comirnaty, may help the body build an effective immune response. This may provide active protection against SARS-CoV-2 infection. LUNAR-COV19 may be safe and tolerable and may generate a better and more durable immune response than the Comirnaty vaccine in adult patients who have received a HCT.

Detailed description

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive LUNAR-COV19 intramuscularly (IM) on days 1, 29 and 113 in the absence of medical conditions or unacceptable toxicity. Additionally, patients undergo nasal swab at screening and at time of suspected SARS-CoV-2 infection, as well as blood sample collection throughout the study.

ARM II: Patients receive SARS-CoV-2 Comirnaty IM on days 1, 29 and 113 in the absence of medical conditions or unacceptable toxicity. Additionally, patients undergo nasal swab at screening and at time of suspected SARS-CoV-2 infection, as well as blood sample collection throughout the study.

After completion of study treatment, patients are followed up at days 115, 120, 127, 141 and 281.

Interventions

  • Biological SARS-CoV-2 mRNA Vaccine ARCT-021
    Given IM
  • Biological Tozinameran
    Given IM
  • Procedure Biospecimen Collection
    Undergo nasal swab and blood sample collection
  • Other Electronic Health Record Review
    Ancillary studies
  • Other Survey Administration
    Ancillary studies

Primary outcome measures

  • Geometric mean titer (GMT) of neutralizing antibody (nAb) against spike protein matching the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant [Time frame: At 28 days after the third vaccine dose, assessed up through day 141]
Secondary outcome measures (8)
  • Percentage of participants with one or more solicited local or systemic reactogenicity signs and symptoms [Time frame: For up to 7 days following each vaccination]
  • Percentage of participants with unsolicited adverse events (AEs) [Time frame: Up to 28 days following each vaccination]
  • Percentage of participants with one or more serious AEs, or AEs of special interest (AESIs) [Time frame: Following first study vaccine dose until 6 months following last vaccination]
  • nAb GMT against spike protein matching the SARS-CoV-2 variant included in the vaccine [Time frame: At 28-84 days after each vaccine dose, and at 6 months after the last dose]
  • Anti-spike immunoglobulin G GMT against Spike protein matching the SARS-CoV-2 variant included in the vaccine [Time frame: At 28-84 days after each vaccine dose, and at 6 months after the last dose]
  • Seroresponse rates [Time frame: At 28-84 days after each vaccine dose, and at 6 months after the last dose]
  • Quantitative levels of anti-Spike T cell responses [Time frame: At 28-84 days after each vaccine dose, and at 6 months after the last dose]
  • New events of late-acute or chronic graft-versus-host disease (GVHD) of grade 3 or higher [Time frame: Up to day 141]

Eligibility criteria

Inclusion criteria

  • Aged ≥ 18 years
  • Willing and able to provide written informed consent, or with a legal representative who can provide informed consent (where locally approved)
  • Have received an allogeneic HCT within the prior 365 days
  • Have no relapse or progression of underlying malignancy
  • Have platelets ≥ 30,000/mm\^3
  • Not pregnant (confirmed with negative urine or serum pregnancy test, if applicable)
  • Willingness to take study vaccine and complete necessary study procedures
  • If of childbearing potential, must agree to use a highly effective method of birth control or abstain from heterosexual activity for the course of the study through at least 60 days after the last dose of the study vaccine

Exclusion criteria

  • Current infection with SARS-CoV-2 or infection within the prior 28 day period
  • Positive for SARS-CoV-2 by nasal swab polymerase chain reaction (PCR) at screening
  • Currently receiving any approved, authorized, or investigational direct-acting antiviral drug against SARS-CoV-2
  • Received any approved, authorized, or investigational monoclonal anti-SARS-CoV-2 antibody therapy within the prior 180 days before screening
  • Received a SARS-CoV-2 vaccine after HCT or within 28 days prior to HCT
  • Participation in any other concurrent clinical trial of an experimental treatment or prevention for SARS-CoV-2
  • Receiving > 1 mg/kg/day corticosteroids within the prior 7 days
  • Active infection that is not adequately controlled, as determined by the investigator
  • Have received therapies that cause profound T-cell or B-cell depletion within 30 days of enrollment, or anticipated to receive such therapies within 3 months of enrollment
  • Have received immunoglobulin replacement therapy (IGRT) within 30 days of enrollment, or anticipated to receive IGRT within 3 months of enrollment
  • Have a history of suspected or documented myocarditis or pericarditis
  • Any inability to take study vaccine or comply with study procedures that, in the opinion of the investigator, would make the participant unsuitable for the study
  • Individuals with a known history of severe hypersensitivity reactions, including anaphylaxis, or other significant adverse reactions to any vaccine or any vaccine excipient. Have any other condition that would, in the investigator's judgment, contraindicate participation in the clinical study due to safety concerns with clinical study procedures

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Prevention

Study locations

United States · 1 center
  • Fred Hutch/University of Washington Cancer Consortium — Seattle

Identifiers

NCT: NCT07390968 · RG1125827 · NCI-2026-00148 · 20962

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗